Duck H5N1 Infection: Clinical Symptoms and HI Titers After Baloxavir Treatment

Yo Shimazu published experimental data on ducks infected with the A/crow/Hokkaido/0103B065/2022 (H5N1) strain. The dataset records clinical symptoms and hemagglutination inhibition titers in serum following administration of baloxavir marboxil at four dosage levels. The data is available as a 12.3 KB Excel file on figshare, last updated in April 2026.

Use Cases

• Compare antiviral efficacy based on dosage levels of baloxavir marboxil mentioned in the description
• Correlate clinical symptom severity with hemagglutination inhibition titers mentioned in the description
• Analyze the response of ducks infected with a specific H5N1 strain mentioned in the description

Strengths

• Data is focused on a specific viral strain (A/crow/Hokkaido/0103B065/2022 (H5N1))
• Includes results from four distinct dosage levels (12.5, 2.5, 0.5, and 0 mg/kg)
• Published under a CC-BY-4.0 license, allowing for reuse

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is very small (12.3 KB), indicating limited scope

Provenance

Source

Yo Shimazu

Collection Method

Likely contains data from a controlled laboratory experiment.

Freshness

Last updated 2026-04-15 17:45:15; freshness should be verified